A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Saved in:
| Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). |
|---|---|
| Authors: | Pinter T; Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com., Klippel Z; Clinical Development, Amgen Inc, Thousand Oaks, CA., Cesas A; Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania., Croitoru A; Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania., Decaestecker J; Department of Oncology, AZ Delta Hospital, Roeselare, Belgium., Gibbs P; Department of Oncology, The Western Hospital, Footscray, Victoria, Australia., Hotko Y; Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine., Jassem J; Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland., Kurteva G; Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria., Novotny J; Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Pleší, Czech Republic., O'Reilly S; Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland., Salek T; Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia., Reiner M; Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA., Morrow PK; Clinical Development, Amgen Inc, Thousand Oaks, CA., Choi MR; Clinical Development, Amgen Inc, Thousand Oaks, CA., Whittaker S; Clinical Development, Amgen Inc, Thousand Oaks, CA., Blanke C; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR. |
| Source: | Clinical colorectal cancer [Clin Colorectal Cancer] 2017 Jun; Vol. 16 (2), pp. 103-114.e3. Date of Electronic Publication: 2016 Sep 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
